D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

Benzinga34minutes ago · Ratings

Lineage Cell Therapeutics Analyst Ratings

Benzinga35minutes ago · Ratings

Lineage Cell Price Target Lowered to $2 From $3 at D. Boral Capital

TipRanks08:10 ET

Daily short sale tracking: Intel's short volume increased by 4 million, with a short sale ratio of 18%

Moomoo NewsDec 31, 2024 09:00 ET

Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $95

Moomoo NewsDec 30, 2024 09:31 ET · Ratings

Lineage To Go Ex-Dividend On December 31st, 2024 With 0.5275 USD Dividend Per Share

Moomoo NewsDec 29, 2024 20:00 ET